卡瑞利珠单抗联合贝伐珠单抗对比卡瑞利珠单抗治疗Ⅲ期肝细胞癌的临床疗效分析  

Comparison of clinical efficacy of carelizumab combined with bevacizumab in the treatment of stage Ⅲ hepatocellularcarcinoma

作　　者：赖奉庭 陈柳风 杨平[1] 蔡广永 Lai Feng-ting;Chen Liu-feng;Yang Ping;Cai Guang-yong(Department of Oncology,Guangdong Agricultural Reclamation Central Hospital,Zhanjiang 524000,Guangdong Province,China)

机构地区：[1]广东省农垦中心医院肿瘤内科,广东湛江524000

出　　处：《中国社区医师》2022年第33期16-18,共3页Chinese Community Doctors

基　　金：湛江市科技计划项目(编号:2020B01308)。

摘　　要：目的:探讨卡瑞利珠单抗联合贝伐珠单抗治疗Ⅲ期肝细胞癌的效果。方法:选取2020年5月-2022年5月广东省农垦中心医院收治的30例Ⅲ期肝细胞癌患者作为研究对象,根据治疗方案的不同分为对照组和观察组,各15例。对照组采用卡瑞利珠单抗单药方案进行治疗,观察组采取卡瑞利珠单抗联合贝伐珠单抗方案进行治疗,对比两组有效率(RR)、疾病控制率(DCR)、无进展生存期(PFS)及总生存期(OS)。结果:观察组RR、DCR均高于对照组,差异有统计学意义(P<0.05);观察组PFS、OS均长于对照组,差异有统计学意义(P<0.05)。结论:卡瑞利珠单抗联合贝伐珠单抗治疗Ⅲ期肝细胞癌的效果优于卡瑞利珠单抗,能有效提高近期疗效,延长患者生存期,值得应用并予以推广。Objective:To investigate the effect of camrelizumab combined with bevacizumab in the treatment of stage Ⅲ hepatocellular carcinoma.Methods:Thirty patients with stage Ⅲ hepatocellular carcinoma treated in Guangdong Agricultural Reclamation Central Hospital from May 2020 to May 2022 were selected as the study subjects.They were divided into control group and observation group according to different treatment schemes,with 15 cases in each group.The control group was treated with camrelizumab,and the observation group was treated with camrelizumab combined with bevacizumab.The response rate(RR),disease control rate(DCR),progression-free survival(PFS),and overall survival(OS)in two groups were compared.Results:The RR and DCR in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The PFS and OS in the observation group were longer than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:The effect of camrelizumab combined with bevacizumab in the treatment of stage Ⅲ hepatocellular carcinoma is better than that of camrelizumab.The combined treatment can improve shortterm efficacy,prolong the survival of patient,and is worthy of application and promotion.

关 键 词：Ⅲ期肝细胞癌 卡瑞利珠单抗 贝伐珠单抗 

分 类 号：R735.7[医药卫生—肿瘤]